Skip to main content

Table 4 Median survival from the time of treatment initiation by variable categories, mRCC patients, Estonia 2004–2012

From: Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

Median survival in months (95% CI)
Total13.7 (11.3–16.2) 
Age group
 15–5911.1 (8.0–17.7)p = 0.667
 60–6914.6 (11.7–20.6) 
 70+13.1 (9.2–19.0) 
Treatment started
 2004–20079.7 (8.1–14.8)p = 0.087
 2008–201215.4 (12.2–19.8) 
Sex
 Male11.9 (9.1–15.4)p = 0.104
 Female18.3 (12.1–22.9) 
Nephrectomy
 Done16.0 (13.1–19.5)p < 0.001
 Not done7.0 (3.8–8.7) 
Histology
 Clear Cell16.1 (12.9–19.5)p = 0.002
 Non-Clear Cell7.0 (4.7–9.7) 
Prognostic group (only 2008–2012)
 Favorable28.4 (22.2–55.7)p < 0.001
 Intermediate13.2 (10.4–16.9) 
 Poor2.4 (1.1–8.5) 
 Unknown15.2 (5.5–21.0)